Neurocrine Biosciences (NBIX) Launches Phase 2 Trial for Alzheimer's Drug NBI-1117567

gurufocus.com · 2026-10-20

On October 20, 2026, Neurocrine Biosciences Inc (NASDAQ: NBIX) announced the initiation of a Phase 2 clinical trial for its experimental Alzheimer's drug candid

TickrTrends take: Neurocrine Biosciences is advancing its pipeline with a Phase 2 trial for an Alzheimer's candidate, which represents clinical progress in a therapeutic area with significant commercial potential. Given TickrTrends' current undervalued assessment of NBIX, investors monitoring the stock's valuation should track whether clinical data from this trial could justify or alter the current valuation multiples assigned to the company. The success or setbacks of this program could become a key factor influencing whether the stock's undervalued status persists or shifts as the market reprices the company's prospects in neurology.

Read the full story at gurufocus.com →